Fibroblast Growth Factor Signaling in Metabolic Regulation
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
The prevalence of obesity is a growing health problem. Obesity is strongly associated with several comorbidities, such as non-alcoholic fatty liver disease, certain cancers, insulin resistance, and type 2 diabetes, which all reduce life expectancy and life quality. Several drugs have been put forward in order to treat these diseases, but many of them have detrimental side effects. The unexpected role of the family of fibroblast growth factors in the regulation of energy metabolism provides new approaches to the treatment of metabolic diseases and offers a valuable tool to gain more insight into metabolic regulation. The known beneficial effects of FGF19 and FGF21 on metabolism, together with recently discovered similar effects of FGF1 suggest that FGFs and their derivatives carry great potential as novel therapeutics to treat metabolic conditions. To facilitate the development of new therapies with improved targeting and minimal side effects, a better understanding of the molecular mechanism of action of FGFs is needed. In this review, we will discuss what is currently known about the physiological roles of FGF signaling in tissues important for metabolic homeostasis. In addition, we will discuss current concepts regarding their pharmacological properties and effector tissues in the context of metabolic disease. Also, the recent progress in the development of FGF variants will be reviewed. Our goal is to provide a comprehensive overview of the current concepts and consensuses regarding FGF signaling in metabolic health and disease and to provide starting points for the development of FGF-based therapies against metabolic conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis
Fisher, F. M., Kleiner, S., Douris, N., Fox, E. C., Mepani, R. J., Verdeguer, F., Wu, J., Kharitonenkov, A., Flier, J. S., Maratos-Flier, E., et al. (2012) · Genes & Development · doi:10.1101/gad.177857.111 · Cited by 1,478 · cited 6×
“These include upregulation of UCP1 and Acetyl CoA Carboxylase 2 (ACC2), increased core body temperature, and increased glucose uptake into BAT (60, 65, 72, 75).”
BackgroundResultInfluentialSREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth
Porstmann, T., Santos, C. R., Griffiths, B., Cully, M., Wu, M., Leevers, S., Griffiths, J. R., Chung, Y.-L., & Schulze, A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.007 · Cited by 1,413
Receptor Specificity of the Fibroblast Growth Factor Family
Zhang, X., Ibrahimi, O. A., Olsen, S. K., Umemori, H., Mohammadi, M., & Ornitz, D. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601252200 · Cited by 1,164 · cited 1×
“The tissue-specific activity of an FGF is thus determined by its affinity for the different FGFRs together with its requirement for binding to polysulfated polysaccharides, β-klotho and integrins (39).”
BackgroundXu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A. (2008) · Endocrinology · doi:10.1210/en.2008-0816 · Cited by 1,031
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885 · cited 3×
“Blood glucose levels on the other hand were not significantly lowered, although a trend was apparent (28).”
BackgroundInfluentialDiabetes, Obesity, and the Brain
Schwartz, M. W., & Porte, D. (2005) · Science · doi:10.1126/science.1104344 · Cited by 841
Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
Fang, S., Suh, J. M., Reilly, S. M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3760 · Cited by 738
Self-citationFon Tacer, K., Bookout, A. L., Ding, X., Kurosu, H., John, G. B., Wang, L., Goetz, R., Mohammadi, M., Kuro-o, M., Mangelsdorf, D. J., et al. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0142 · Cited by 700
Lin, Z., Tian, H., Lam, K. S. L., Lin, S., Hoo, R. C. L., Konishi, M., Itoh, N., Wang, Y., Bornstein, S. R., Xu, A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.005 · Cited by 691 · cited 1×
“Interestingly, the decrease in fat mass and body weight upon FGF21 treatment was still present in adiponectin-KO mice (albeit less than in FGF21-treated obese WT mice), indicating that these effects are independent of adiponectin (61, 62).”
BackgroundFGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis
Kir, S., Beddow, S. A., Samuel, V. T., Miller, P., Previs, S. F., Suino-Powell, K., Xu, H. E., Shulman, G. I., Kliewer, S. A., & Mangelsdorf, D. J. (2011) · Science · doi:10.1126/science.1198363 · Cited by 637
Thermogenic Activation Induces FGF21 Expression and Release in Brown Adipose Tissue
Hondares, E., Iglesias, R., Giralt, A., Gonzalez, F. J., Giralt, M., Mampel, T., & Villarroya, F. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.215889 · Cited by 623 · cited 3×
“However, the effects of FGF21 on thermogenesis by regulating the nervous system cannot be excluded, since it has been shown that FGF21 also affects energy homeostasis via the brain, which in turn regulates neuronal output to peripheral organs (50, 51, 72, 73).”
BackgroundβKlotho is required for metabolic activity of fibroblast growth factor 21
Ogawa, Y., Kurosu, H., Yamamoto, M., Nandi, A., Rosenblatt, K. P., Goetz, R., Eliseenkova, A. V., Mohammadi, M., & Kuro-o, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701600104 · Cited by 617 · cited 3×
“KO or knockdown of β-klotho results in the ablation of FGF21 signaling in WAT, both in vitro and in vivo, and eliminates its beneficial effects in obese rodents (37, 47, 63, 64).”
BackgroundCirculating FGF21 Is Liver Derived and Enhances Glucose Uptake During Refeeding and Overfeeding
Markan, K. R., Naber, M. C., Ameka, M. K., Anderegg, M. D., Mangelsdorf, D. J., Kliewer, S. A., Mohammadi, M., & Potthoff, M. J. (2014) · Diabetes · doi:10.2337/db14-0595 · Cited by 590 · cited 2×
“Based on the finding that mice with a liver-specific deletion of FGF21 displayed reduced peripheral insulin sensitivity, it has been hypothesized that upon refeeding after prolonged fasting, hepatic FGF21 communicates with other tissues to induce adequate refeeding responses, thereby helps in overcoming fasting-associ…”
BackgroundTomlinson, E., Fu, L., John, L., Hultgren, B., Huang, X., Renz, M., Stephan, J. P., Tsai, S. P., Powell-Braxton, L., French, D., et al. (2002) · Endocrinology · doi:10.1210/endo.143.5.8850 · Cited by 576
FGF21 regulates metabolism and circadian behavior by acting on the nervous system
Bookout, A. L., de Groot, M. H. M., Owen, B. M., Lee, S., Gautron, L., Lawrence, H. L., Ding, X., Elmquist, J. K., Takahashi, J. S., Mangelsdorf, D. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3249 · Cited by 545 · cited 5×
“org regulation of circadian rhythms and the adaptive starvation response, which includes suppression of female reproduction and physical activity and the systemic increase of glucocorticoids (50).”
BackgroundInfluentialDutchak, P. A., Katafuchi, T., Bookout, A. L., Choi, J. H., Yu, R. T., Mangelsdorf, D. J., & Kliewer, S. A. (2012) · Cell · doi:10.1016/j.cell.2011.11.062 · Cited by 537
Self-citationFGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss
Owen, B. M., Ding, X., Morgan, D. A., Coate, K. C., Bookout, A. L., Rahmouni, K., Kliewer, S. A., & Mangelsdorf, D. J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.07.012 · Cited by 523 · cited 3×
“It is also possible that FGF21 signaling in the brain affects the sympathetic outflow to the heart, similar to BAT (19).”
BackgroundKong, B., Wang, L., Chiang, J. Y. L., Zhang, Y., Klaassen, C. D., & Guo, G. L. (2012) · Hepatology · doi:10.1002/hep.25740 · Cited by 456
Suomalainen, A., Elo, J. M., Pietiläinen, K. H., Hakonen, A. H., Sevastianova, K., Korpela, M., Isohanni, P., Marjavaara, S. K., Tyni, T., Kiuru-Enari, S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70155-7 · Cited by 427
Wei, W., Dutchak, P. A., Wang, X., Ding, X., Wang, X., Bookout, A. L., Goetz, R., Mohammadi, M., Gerard, R. D., Dechow, P. C., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200797109 · Cited by 426
FGF21 is an Akt‐regulated myokine
Izumiya, Y., Bina, H. A., Ouchi, N., Akasaki, Y., Kharitonenkov, A., & Walsh, K. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.10.021 · Cited by 415 · cited 1×
“FGF21 protein was detected in muscle of fasted mice and was upregulated in gastrocnemius muscle of skeletal muscle-specific Akt1-transgenic mice (123).”
BackgroundβKlotho Is Required for Fibroblast Growth Factor 21 Effects on Growth and Metabolism
Ding, X., Boney-Montoya, J., Owen, B. M., Bookout, A. L., Coate, K. C., Mangelsdorf, D. J., & Kliewer, S. A. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.08.002 · Cited by 403
Hondares, E., Rosell, M., Gonzalez, F. J., Giralt, M., Iglesias, R., & Villarroya, F. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.02.001 · Cited by 377 · cited 1×
“Another observation that stresses the importance of FGF21 in thermogenesis is that hepatic activation of PPARα by fatty acids from milk and subsequent induction of FGF21 is crucial for adequate BAT activation and thermogenesis in newborn mice (74).”
BackgroundA Mouse Model of Hepatocellular Carcinoma
Nicholes, K., Guillet, S., Tomlinson, E., Hillan, K., Wright, B., Frantz, G. D., Pham, T. A., Dillard-Telm, L., Tsai, S. P., Stephan, J.-P., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61177-7 · Cited by 359
Suzuki, M., Uehara, Y., Motomura-Matsuzaka, K., Oki, J., Koyama, Y., Kimura, M., Asada, M., Komi-Kuramochi, A., Oka, S., & Toru, T. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0313 · Cited by 345
Mitochondrial myopathy induces a starvation-like response
Tyynismaa, H., Carroll, C. J., Raimundo, N., Ahola-Erkkilä, S., Wenz, T., Ruhanen, H., Guse, K., Hemminki, A., Peltola-Mjøsund, K. E., Tulkki, V., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq310 · Cited by 300
Berglund, E. D., Li, C. Y., Bina, H. A., Lynes, S. E., Michael, M. D., Shanafelt, A. B., Kharitonenkov, A., & Wasserman, D. H. (2009) · Endocrinology · doi:10.1210/en.2009-0221 · Cited by 297 · cited 1×
“Some studies report an improvement of glucose uptake into the muscle after FGF21 injection in obese mice (which could be a direct or an indirect effect), while others did not find this (75, 121).”
BackgroundTissue-specific actions of the metabolic hormones FGF15/19 and FGF21
Owen, B. M., Mangelsdorf, D. J., & Kliewer, S. A. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.10.002 · Cited by 286
The fasting polypeptide FGF21 can enter brain from blood
Hsuchou, H., Pan, W., & Kastin, A. J. (2007) · Peptides · doi:10.1016/j.peptides.2007.10.007 · Cited by 280
The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue
Adams, A. C., Yang, C., Coskun, T., Cheng, C. C., Gimeno, R. E., Luo, Y., & Kharitonenkov, A. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2012.08.007 · Cited by 266 · cited 10×
“FGF1, FGF19, and FGF21 regulate different metabolic processes through different cell types and tissues, of which the WAT, CNS, and the liver seem to be the main players (3, 4, 11, 14, 16, 18, 19).”
BackgroundInfluentialBrown Adipose Tissue Responds to Cold and Adrenergic Stimulation by Induction of FGF21
Chartoumpekis, D. V., Habeos, I. G., Ziros, P. G., Psyrogiannis, A. I., Kyriazopoulou, V. E., & Papavassiliou, A. G. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00075 · Cited by 252
Foltz, I. N., Hu, S., King, C., Wu, X., Yang, C., Wang, W., Weiszmann, J., Stevens, J., Chen, J. S., Nuanmanee, N., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004690 · Cited by 211 · cited 1×
“Since the metabolic effects of mimAb1 were not observed in WAT-specific FGFR1 KO mice, it was suggested that these effects are mainly mediated though the adipose tissue (150).”
BackgroundPharmacologic Effects of FGF21 Are Independent of the “Browning” of White Adipose Tissue
Véniant, M. M., Sivits, G., Helmering, J., Komorowski, R., Lee, J., Fan, W., Moyer, C., & Lloyd, D. J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.04.019 · Cited by 204
Fibroblast Growth Factor-21 Is Induced in Human Skeletal Muscles by Hyperinsulinemia
Hojman, P., Pedersen, M., Nielsen, A. R., Krogh-Madsen, R., Yfanti, C., Åkerstrom, T., Nielsen, S., & Pedersen, B. K. (2009) · Diabetes · doi:10.2337/db09-0713 · Cited by 198
Lack of Overt FGF21 Resistance in Two Mouse Models of Obesity and Insulin Resistance
Hale, C., Chen, M. M., Stanislaus, S., Chinookoswong, N., Hager, T., Wang, M., Véniant, M. M., & Xu, J. (2012) · Endocrinology · doi:10.1210/en.2010-1262 · Cited by 185 · cited 1×
“FGF21 is considered a typical fasting hormone and although seemingly paradoxical, circulating FGF21 levels are also elevated during obesity (12).”
BackgroundRyan, K. K., Kohli, R., Gutierrez-Aguilar, R., Gaitonde, S. G., Woods, S. C., & Seeley, R. J. (2013) · Endocrinology · doi:10.1210/en.2012-1891 · Cited by 185
FGF21 Requires βklotho to Act In Vivo
Adams, A. C., Cheng, C. C., Coskun, T., & Kharitonenkov, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049977 · Cited by 181
Exercise increases serum fibroblast growth factor 21 (FGF21) levels
Cuevas-Ramos, D., Almeda-Valdés, P., Meza-Arana, C. E., Brito-Córdova, G., Gómez-Pérez, F. J., Mehta, R., Oseguera-Moguel, J., & Aguilar-Salinas, C. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038022 · Cited by 178
FGF21-based pharmacotherapy – potential utility for metabolic disorders
Gimeno, R. E., & Moller, D. E. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.03.001 · Cited by 163 · cited 1×
“The results of this research have been recently extensively described (143, 144).”
BackgroundDiscrete Aspects of FGF21 In Vivo Pharmacology Do Not Require UCP1
Samms, R. J., Smith, D. P., Cheng, C. C., Antonellis, P. P., Perfield, J. W., Kharitonenkov, A., Gimeno, R. E., & Adams, A. C. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.046 · Cited by 154 · cited 1×
“(82), who showed that UCP1 KO mice still displayed improved glycemic control and improved lipid profiles, and showed weight loss mainly due to decreased food intake.”
BackgroundFGF21 N‐ and C‐termini play different roles in receptor interaction and activation
Yie, J., Hecht, R., Patel, J., Stevens, J., Wang, W., Hawkins, N., Steavenson, S., Smith, S., Winters, D., Fisher, S., et al. (2009) · FEBS Letters · doi:10.1016/j.febslet.2008.11.023 · Cited by 149 · cited 1×
“Using C-terminal and N-terminal deletion mutants, it has been shown that, similar to FGF19, the C-terminus of FGF21 is required for β-klotho interaction, whereas the N-terminus drives efficient FGFR activation (Figure 2) (140, 142).”
BackgroundDifferent roles of N‐ and C‐ termini in the functional activity of FGF21
Micanovic, R., Raches, D. W., Dunbar, J. D., Driver, D. A., Bina, H. A., Dickinson, C. D., & Kharitonenkov, A. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21675 · Cited by 146
FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic–pituitary–adrenal axis
Perry, R. J., Lee, S., Ma, L., Zhang, D., Schlessinger, J., & Shulman, G. I. (2015) · Nature Communications · doi:10.1038/ncomms7980 · Cited by 132 · cited 1×
“infusion of both FGF1 and FGF19 suppressed the hypothalamic–pituitary–adrenal (HPA) axis, resulting in a decrease in hepatic glucose production, hepatic acetyl CoA content and whole-body lipolysis (109).”
BackgroundHuang, J., Ishino, T., Chen, G., Rolzin, P., Osothprarop, T. F., Retting, K., Li, L., Jin, P., Matin, M. J., Huyghe, B., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.204420 · Cited by 121 · cited 1×
“In short, approaches to improve FGF21 bio-stability include the addition of an Fc fragment to the N-terminus, the introduction of non-native disulfide bonds and subsequent PEG-ylation, and conjugation of FGF21 to a scaffold antibody (141, 145, 146).”
BackgroundFundamentals of FGF19 & FGF21 Action In Vitro and In Vivo
Adams, A. C., Coskun, T., Irizarry Rovira, A. R., Schneider, M. A., Raches, D. W., Micanovic, R., Bina, H. A., Dunbar, J. D., & Kharitonenkov, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038438 · Cited by 109 · cited 2×
“Pharmacological administration of FGF19 to obese diabetic rodents elicits beneficial effects on the metabolism that are highly similar to FGF21 administration (57).”
BackgroundKolumam, G., Chen, M. Z., Tong, R., Zavala-Solorio, J., Kates, L., van Bruggen, N., Ross, J., Wyatt, S. K., Gandham, V. D., Carano, R. A. D., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.05.028 · Cited by 108 · cited 1×
“Interestingly, it did induce signaling in the adipose tissues and pancreas, but not in the liver and brain (152).”
BackgroundFGF21-Mediated Improvements in Glucose Clearance Require Uncoupling Protein 1
Kwon, M. M., O’Dwyer, S. M., Baker, R. K., Covey, S. D., & Kieffer, T. J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.021 · Cited by 77 · cited 1×
“However, their data suggest that FGF21-dependent glucose clearance requires UCP1 protein (83).”
BackgroundMuise, E. S., Souza, S., Chi, A., Tan, Y., Zhao, X., Liu, F., Dallas-yang, Q., Wu, M., Sarr, T., Zhu, L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073011 · Cited by 57 · cited 3×
“The so-called “browning” of WAT is characterized by the appearance of brown-like adipocytes in WAT, a process normally induced by cold or β-adrenergic stimulation (67, 72, 76, 77).”
Background
Cited by
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
Rotman, Y., & Sanyal, A. J. (2017) · Gut · doi:10.1136/gutjnl-2016-312431 · Cited by 410
Bile acids and their receptors in metabolic disorders
Fiorucci, S., Distrutti, E., Carino, A., Zampella, A., & Biagioli, M. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101094 · Cited by 258
Treatment options for alcoholic and non-alcoholic fatty liver disease: A review
Singh, S., Osna, N. A., & Kharbanda, K. K. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6549 · Cited by 257
The road ahead for health and lifespan interventions
Gonzalez-Freire, M., Diaz-Ruiz, A., Hauser, D., Martinez-Romero, J., Ferrucci, L., Bernier, M., & de Cabo, R. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101037 · Cited by 118
Metadata
- Authors
- Nies, V. J. M., Sancar, G., Liu, W., van Zutphen, T., Struik, D., Yu, R. T., Atkins, A. R., Evans, R. M., Jonker, J. W., & Downes, M. R.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2016-01-19
- Volume
- 6
- Pages
- 193-193
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2234735029
- Cited by
- 136
- References
- 53
- FWCI
- 9.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.